



US009226940B2

(12) **United States Patent**
Roberts

(10) **Patent No.:** **US 9,226,940 B2**

(45) **Date of Patent:** **Jan. 5, 2016**

(54) **METHOD OF TREATING OCULAR DISORDERS**

A61K 31/352 (2006.01)
A61K 33/04 (2006.01)
A61K 33/30 (2006.01)

(71) Applicant: **Kemin Industries, Inc.**, Des Moines, IA (US)

(52) **U.S. CL.**
CPC *A61K 33/34* (2013.01); *A61K 31/00* (2013.01); *A61K 31/015* (2013.01); *A61K 31/047* (2013.01); *A61K 31/05* (2013.01); *A61K 31/07* (2013.01); *A61K 31/085* (2013.01); *A61K 31/11* (2013.01); *A61K 31/352* (2013.01); *A61K 31/353* (2013.01); *A61K 31/355* (2013.01); *A61K 31/375* (2013.01); *A61K 33/04* (2013.01); *A61K 33/30* (2013.01); *A61K 45/06* (2013.01)

(72) Inventor: **Richard Roberts**, Johnston, IA (US)

(73) Assignee: **Kemin Industries, Inc.**, Des Moines, IA (US)

(*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 0 days.

(58) **Field of Classification Search**
IPC *A61K 31/07, 8/687, 8/347*
See application file for complete search history.

(21) Appl. No.: **14/307,684**

(22) Filed: **Jun. 18, 2014**

(56) **References Cited**

(65) **Prior Publication Data**

U.S. PATENT DOCUMENTS

US 2014/0302169 A1 Oct. 9, 2014

2007/0082064 A1 4/2007 Krawitz

Related U.S. Application Data

OTHER PUBLICATIONS

(62) Division of application No. 13/238,939, filed on Sep. 21, 2011, now Pat. No. 8,815,955.

Shaban et al., "A2E and blue light in the retina: the paradigm of age-related macular degeneration," *Biological Chemistry* 383(3-4):537-545, 2002.*

(60) Provisional application No. 61/384,958, filed on Sep. 21, 2010.


(Continued)

(51) **Int. Cl.**
A61K 33/34 (2006.01)
A61K 31/00 (2006.01)
A61K 31/015 (2006.01)
A61K 31/047 (2006.01)
A61K 31/05 (2006.01)
A61K 31/07 (2006.01)
A61K 31/11 (2006.01)
A61K 31/353 (2006.01)
A61K 31/355 (2006.01)
A61K 31/375 (2006.01)
A61K 45/06 (2006.01)
A61K 31/085 (2006.01)

Primary Examiner—Rosanne Kosson
(74) *Attorney, Agent, or Firm*—Davis, Brown, Koehn, Shors & Roberts, P.C.; Kent A. Herink

(57) **ABSTRACT**
A method wherein subjects having or at risk for having hyperopia, presbyopia or astigmatism are administered a composition having an effective amount of ocular antioxidants, including specifically macular pigments, to prevent, treat, or delay the onset of age-related macular degeneration (AMD).

13 Claims, 4 Drawing Sheets



PMIC 百醫科技
僅供線上瀏覽查詢，未經同意請勿任意轉載